Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
FDA approves supplement for Merck's Enflonsia (clesrovimab-cfor)Oct 14Regulatory decisionclesrovimabMerck & Co., Inc.
Sign inSign in